Weike Medical Launches D-shufo™ Next-Gen PFO Occluder, Files IPO Prospectus
Vickor
Structural Heart Disease Minimally Invasive Intervention Product Developer
Foramen OvaleIt is a natural passage in the atrial septum of the heart, responsible for supplying blood to the heart during embryonic development. However, after birth, this passage usually closes naturally. If the foramen ovale does not close after the age of 3, this condition is called "patent foramen ovale."Patent Foramen Ovale (PFO)Generally understood as abnormal cardiovascular structures, it has a high incidence rate and is also one of the most common congenital heart abnormalities in adults, with approximately 1/4 of adults suffering from this condition.
Most patients are asymptomatic, but its presence poses a potential danger to health or lifespan. Under specific circumstances,This can lead to a series of clinical symptoms, including migraine, ischemic stroke, myocardial infarction, peripheral vascular embolism, decompression sickness, etc.Studies show that the risk of stroke, migraine, etc. is several times higher in people with patent foramen ovale (PFO) compared to the normal population, and the probability of patients with stroke, migraine, etc. having this condition is also higher than that of the general population.
In order to effectively address these issues,Percutaneous interventional closure of the foramen ovaleHas become a recommended treatment method aimed at preventing the recurrence of stroke events and alleviating migraine attacks.
In February 2024, Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") independently developedD-shufo™ New Generation PFO OccluderReceived registration approval for marketing from the National Medical Products Administration (NMPA)。D-shufo™ PFO Occluder is not only the second domestically produced nickel-titanium alloy occluder approved for marketing in China, but alsoThe most comprehensive range of PFO occluders currently available on the market。
At 19:30 on Wednesday, May 29th, the 64th session of VCBeat's New Product Review invited Li Huijia, Marketing Director of Vickor, and Li Hekang, Regional Sales Director of Vickor.Independently Developed "D-shufo™ New Generation PFO Occluder"Product Promotion.
1. Made from mature nickel-titanium alloy wire, it offers excellent shape memory and elasticity for stable clamping performance. After 20 years of clinical validation, its safety and stability have gained widespread trust.
2. Parylene surface coating technology effectively blocks nickel ion release and reduces allergic reactions;
3. Disc-shaped inward structure, closely fitting the atrial septum after release, reducing residual shunt;
4. The left disc is designed without rivets, promoting endothelialization and reducing the occurrence of thrombosis in the left heart;
5. Twelve specifications and models, finely adjusted disc and waist diameters, unique left-large-right-small disc specifications, can adapt to complex patent foramen ovale shapes, improving the success rate of closure.
Scan the QR code on the poster to add the assistant and schedule a live broadcast.
Li Huijia
Vickor Medical Market Director
More than 10 years of experience in high-value consumables and innovative device marketing, including market promotion, new product launch access, and full lifecycle product management.
Li and Kang
Vickor Medical Sales Director of Greater Region
15 years of experience in structural heart disease device sales, former Sales Director of a domestic structural products company.
About Vickor
Wuhan Vickor Medical Technology Co., Ltd. was established in July 2018, focusing on major clinical needs in the cardiovascular field, especially in the minimally invasive interventional treatment of heart failure and structural heart diseases. Through research and development, technical services, production, and sales, it is committed to building an innovative medical device platform that provides full-cycle cardiovascular solutions, offering optimized products and treatment options for patients and doctors worldwide.
The company's headquarters is located in Wuhan East Lake High-tech Zone, with an industrial chain layout upstream and downstream in Suzhou, Beijing, Shanghai, and other places. The company’s founder and research team are composed of experts in interventional treatment for structural heart disease, cardiac surgery experts, metal materials experts, braided device R&D experts, and medical device registration experts, forming a strong integration of medical research and enterprise.
Products cover multiple fields, including atrial shunt devices for heart failure prevention and treatment, patent foramen ovale closure devices for the prevention of cardiogenic stroke, transcatheter aortic valve replacement systems for valvular disease treatment, and related surgical accessories and consumables. More than 60 patents have been applied for, including over 50 invention patents, 10 utility model patents, and 3 PCT patents. The relevant products possess complete independent intellectual property rights. The atrial shunt device has received designation under NMPA’s "Special Review Procedure for Innovative Medical Devices" and FDA’s "Breakthrough Device Designation."
About VCBeat's New Product Review
"VCBeat New Product Review," is a live broadcast column under "VCBeat" that supports the release of innovative medical products. The column's mission is: to assist in the milestone release of every medical innovation product.
Scan the QR code below to contact the assistant and schedule a live broadcast.
(If already added, please actively inquire with the assistant.)
